Jasper Therapeutics (JSPRW) Stock Analysis

What Jasper Therapeutics does

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Key metrics

ETFs linked to JSPRW

Broad-market and Healthcare sector ETFs an investor holding Jasper Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how JSPRW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Jasper Therapeutics?

Jasper Therapeutics trades under the ticker JSPRW on NASDAQ.

Which exchange is JSPRW listed on?

JSPRW is listed on NASDAQ.

What sector does Jasper Therapeutics operate in?

Jasper Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze JSPRW in a portfolio?

PortView shows JSPRW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.